LOXO ONCOLOGY,INC. (NASDAQ:LOXO) Files An 8-K Entry into a Material Definitive Agreement

ME Staff 8-k
-
0

LOXO ONCOLOGY,INC. (NASDAQ:LOXO) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement.

The information contained in Item 2.01 below is incorporated into this Item 1.01 by reference.

Item 2.01. Completion of Acquisition or Disposition of Assets.

On July28, 2017, Loxo Oncology,Inc. (“Loxo Oncology”) entered into and closed on an Agreement for the Assignment of Patents and other Rights and for the Novation of Certain Agreements, including for Product Manufacturing (the “Agreement”) with Redx Pharma Plc and Redx Oncology Limited (acting by the joint administrators of those companies, Mr.Jason Baker and Mr.Miles Needham of FRP Advisory LLP) (collectively “Redx”), to which Loxo Oncology acquired patents and other rights related to the Redx BTK discovery program, including lead candidate LOXO-305 (formerly RXC005) (the “Redx Assets”). In consideration for the acquisition of the Redx Assets, Loxo Oncology paid a purchase price of $40 million. The Agreement is unconditional and the sale is not subject to representations and warranties. Loxo Oncology is not subject to milestone or royalty payments, and Redx is subject to non-competition provisions for three years following the sale.

A press release announcing the acquisition of the Redx Assets is filed with this Current Report on Form8-K as Exhibit99.1 and incorporated into this Item 2.01 by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits


Loxo Oncology, Inc. Exhibit
EX-99.1 2 a17-18591_1ex99d1.htm EX-99.1 Exhibit 99.1     Loxo Oncology Announces Acquisition of Highly Selective,…
To view the full exhibit click here

About LOXO ONCOLOGY,INC. (NASDAQ:LOXO)

Loxo Oncology, Inc. is a United States-based biopharmaceutical company. The Company is engaged in developing selective medicines for patients with genetically defined cancers. Its pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer. Its pipeline includes LOXO-101, LOXO-195, Rearranged During Transfection (RET) Program and Fibroblast Growth Factor Receptor (FGFR) program. LOXO-101 is a selective inhibitor of tropomyosin receptor kinases (TRK) for the treatment of patients with soft tissue sarcoma. LOXO-195 is a selective TRK inhibitor capable of addressing potential mechanisms of acquired resistance that may emerge in patients receiving LOXO-101 or multikinase inhibitors with anti-TRK activity. It has designed a series of RET inhibitors that optimize on-target potency for RET gene fusions, mutations and clinically-identified resistance mutations. It is designing FGFR1-sparing FGFR inhibitor.